Clinical Trials Logo

Cardiac Event clinical trials

View clinical trials related to Cardiac Event.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04433546 Terminated - Pneumonia Clinical Trials

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

VANGARD
Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

NCT ID: NCT03208023 Terminated - Clinical trials for Fluid Responsiveness

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

RESIPI
Start date: October 9, 2017
Phase: N/A
Study type: Interventional

This study aims to evaluate the effect of a novel hemodynamic management and monitoring strategy for reducing cardiac bio marker elevations and major adverse cardiac events.